{"id":271,"date":"2025-07-30T13:56:00","date_gmt":"2025-07-30T08:26:00","guid":{"rendered":"https:\/\/www.najao.com\/learn\/?p=271"},"modified":"2026-02-08T04:32:08","modified_gmt":"2026-02-07T23:02:08","slug":"oncolytic-viruses","status":"publish","type":"post","link":"https:\/\/www.najao.com\/learn\/oncolytic-viruses\/","title":{"rendered":"Oncolytic Viruses: Viruses as Cancer Killers"},"content":{"rendered":"\n

The fight against cancer<\/a> is a relentless one, and scientists are tirelessly working on seeking innovative and potent solutions to its challenges. One of the most exciting recent advancements on this front has been Oncolytic Viruses (OVs)<\/strong>\u2014a unique and ingenious class of viruses that have been remodeled to specifically target, infect, replicate within, and ultimately destroy cancer cells, while leaving healthy cells unharmed1<\/sup><\/strong>.<\/p>\n\n\n\n

The dual nature of these viruses is somewhat evident from their etymology: “onco” meaning cancer, and “lytic”, describing the process of breaking open of cells. More so, OVs do not just directly kill cells; they serve as potent immune stimulators, leveraging the body’s own defense system to launch a systemic attack against cancer2<\/sup><\/strong>. This dual mechanism positions itself at the helm of modern cancer immunotherapy<\/a>.<\/p>\n\n\n\n

A historical perspective<\/h2>\n\n\n\n

The concept of using viruses to fight cancer dates back as far as the late 19th and early 20th centuries, when doctors observed that in some cancer patients with viral infections, tumors regressed spontaneously3<\/sup><\/strong>. These early observations paved the way for “virotherapy,” a broader concept that uses bacteriophages in phage therapy<\/a> for bacterial infections, whereby viruses are similarly leveraged for their lytic capabilities. However, this concept has evolved further with the recent advent of sophisticated genetic engineering tools, allowing scientists to precisely modify naturally occurring viruses into highly effective, targeted, and safer therapeutic agents.<\/p>\n\n\n\n

How oncolytic viruses work<\/h2>\n\n\n\n

The potency of oncolytic viruses lies in their remarkable twofold attack on cancer:<\/p>\n\n\n\n

Selective cancer cell infection and lysis<\/h3>\n\n\n\n

Oncolytic viruses can either naturally possess a preference for cancer cells or can be specifically engineered to do so4<\/sup><\/strong>. This selectivity often stems from inherent defects in the antiviral defense pathways of cancer cells, or their overexpression of certain cell surface receptors that viruses exploit. For instance, many cancer cells have impaired interferon responses that make them vulnerable to viral replication where healthy cells would typically fight off infection5<\/sup><\/strong>.<\/p>\n\n\n\n

Modern OVs are often genetically modified to enhance this tumor-specific targeting property, by deleting viral genes essential for replication in normal cells but not in cancer cells, or by inserting genes that are only activated within the tumor microenvironment6,<\/sup><\/strong> 4<\/sup><\/strong>.<\/p>\n\n\n\n

Once inside a cancer cell, the virus replicates rapidly, overwhelming the cell’s internal machinery. This unchecked replication causes the cancer cell to burst open by a process called lysis, releasing a fresh batch of new virus particles7<\/sup><\/strong>. These new virions then create a self-amplifying cycle of destruction that proliferates throughout the tumor mass, infecting nearby cancer cells.<\/p>\n\n\n\n

Immune system activation<\/h3>\n\n\n\n

The direct killing of cancer cells by OVs is only half the story, and not even the most critical part. As the cancer cells undergo lysis, they release “danger signals” and tumor-specific antigens7<\/sup><\/strong>. These antigens are essentially molecular fingerprints unique to the cancer cells or highly abundant on them.<\/p>\n\n\n\n

These released tumor antigens and viral antigens are then “picked up” by specialized immune cells known as antigen-presenting cells (APCs), such as dendritic cells8<\/sup><\/strong>. APCs act as vital messengers, traveling to the body’s lymph nodes, where they “present” these captured antigens to T-cells9<\/sup><\/strong>. This crucial interaction activates a powerful anti-tumor T-cell response.<\/p>\n\n\n\n

These newly activated T-cells then travel throughout the body, specifically targeting and destroying cancer cells, not only in the directly injected tumor but also, remarkably, in distant metastatic sites that were never directly infected by the virus. This phenomenon is known as the “bystander effect” or, when affecting distant tumors, the “abscopal effect”10<\/sup><\/strong>.<\/p>\n\n\n\n

Furthermore, OVs can be engineered to carry and express additional immune-stimulating molecules, such as cytokines (eg, GM-CSF), directly within the tumor11<\/sup><\/strong>. This helps to recruit more immune cells, turning “cold” (immune-desert) tumors, which are often resistant to other immunotherapies \u2013 into “hot” (immune-inflamed) tumors that are more likely to mount an immune attack12<\/sup><\/strong>.<\/p>\n\n\n\n

Key oncolytic virus types<\/h2>\n\n\n\n

Several variants of viruses are now being explored and engineered for oncolytic virotherapy, with some already approved for clinical use:<\/p>\n\n\n\n